Skip to main content

Advertisement

Table 1 The causal prophylactic activities of tafenoquine (TQ) and primaquine (PQ) by using real time in vivo image system (IVIS) following single dose (-1 or 0 day after inoculation) or daily oral administrations for 3 days multiple doses (-1, 0, and 1 day after infection) against challenge with 50,000 sporozoites of the ANKA strain of P. berghei intravenously in male C57BL/6 albino mice with positive and negative controls (n = 5–20 each)

From: Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections

Test agents Dose (mg/kg) Oral dose Date of dosing Suppression rate (%) IVIS* Blood Infection by FCM* Number of C57BL/albino mice Delay in patency (days after onset in controls) Effects
     24 h 48 h 72 h   Challenged Protected completely Causal prophylaxis   
Tafenoquine 10 3 days -1, 0, 1 100 100 100 0/5 5 5 5/5 - Full CP
5 3 days -1, 0, 1 90.4 100 100 0/13 13 13 13/13 - Full CP
2.5 3 days -1, 0, 1 100 100 100 2/5 5 3 3/5 - Partial CP
1.25 3 days -1, 0, 1 84.7 92.3 98.9 4/5 5 1 1/5 2,4,4,7 Suppression
5 Single -1 68.7 98.6 100 0/10 10 10 10/10 - Full CP
5 Single 0 66.0 91.1 98.5 4/5 5 1 1/5 4,2,4,9 Partial CP
Primaquine 25 3 days -1, 0, 1 100 100 100 0/10 10 10 10/10 - Full CP
20 3 days -1, 0, 1 100 100 100 1/10 10 9 9/10 6 Partial CP
15 3 days -1, 0, 1 100 100 100 4/20 20 16 16/20 2,2,2,1 Partial CP
10 3 days -1, 0, 1 100 97.6 100 5/10 10 5 5/10 2,4,2,2,4 Partial CP
5 3 days -1, 0, 1 82.4 77.5 89.4 5/5 5 0 0/5 2,2 Suppression
25 Single -1 45.7 0 0 5/5 5 0 0/5 - Suppression
  25 Single 0 11.2 0 0 5/5 5 0 0/5 - Suppression
  1. *The infection was determined by recording the onset of IVIS for liver stage and parasitaemia for blood stage by using a flow cytometry system (FCM).
  2. CP = causal prophylaxis.